Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Beacon Harbor Wealth Advisors Inc.

Beacon Harbor Wealth Advisors Inc. decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,696 shares of the company’s stock after selling 53 shares during the quarter. Medpace accounts for approximately 1.8% of Beacon Harbor Wealth Advisors Inc.’s portfolio, making the stock its 20th largest holding. Beacon Harbor Wealth Advisors Inc. owned 0.06% of Medpace worth $6,037,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in shares of Medpace by 353.2% in the 3rd quarter. SG Americas Securities LLC now owns 2,515 shares of the company’s stock valued at $609,000 after purchasing an additional 1,960 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Medpace by 20.2% in the third quarter. Commonwealth Equity Services LLC now owns 2,765 shares of the company’s stock valued at $669,000 after buying an additional 465 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Medpace by 13.3% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,755 shares of the company’s stock worth $909,000 after buying an additional 440 shares during the period. FinTrust Capital Advisors LLC purchased a new position in shares of Medpace during the 3rd quarter valued at approximately $30,000. Finally, GW Henssler & Associates Ltd. acquired a new stake in Medpace in the 3rd quarter valued at $208,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 15,102 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the sale, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Medpace news, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the sale, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The disclosure for this sale can be found here. Insiders have sold a total of 204,442 shares of company stock worth $82,702,867 in the last quarter. Company insiders own 20.30% of the company’s stock.

Medpace Trading Down 0.5 %

MEDP stock traded down $1.95 during mid-day trading on Thursday, reaching $395.91. The company’s stock had a trading volume of 102,596 shares, compared to its average volume of 249,280. The company’s 50 day moving average is $398.32 and its two-hundred day moving average is $328.94. Medpace Holdings, Inc. has a fifty-two week low of $197.39 and a fifty-two week high of $421.00. The stock has a market cap of $12.27 billion, a PE ratio of 40.79, a P/E/G ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same period in the prior year, the business earned $2.27 earnings per share. The business’s revenue was up 17.7% compared to the same quarter last year. On average, analysts forecast that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on MEDP shares. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Robert W. Baird upped their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Guggenheim lifted their price objective on Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and raised their target price for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $443.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.